IGF1 and breast cancer: In the orthotopic 4T1.2 breast cancer model, we demonstrate that the expression of a protease-resistant IGFBP4, where the PAPP-A cleavage site has been mutated without altering its IGF-binding capacity, inhibited 4T1.2 tumour growth.